ESTRO 2024 - Abstract Book

S2383

Clinical - Urology

ESTRO 2024

(PRISMA) guidelines were followed to identify eligible studies. Data extraction and risk of bias assessment were performed following predefined criteria.

Results:

A total of 49 studies met our inclusion criteria, including three phase III randomized trials. Cisplatin based protocols were the most commonly used CC. 5-fluorouracile and Mitomycin C (5FU-MMC) and Carbogen-Nicotinamide are supported by the highest level of evidence. An important heterogeneity in patient selection, treatment modalities, follow up and reported outcomes does not allow for comparability amongst trials. Overall, survival outcomes were similar regardless of CC, with a 5-year OS of around 50%. Bladder preservation ranged from 60% to 90%. Distant metastasis rates varied from 10% to 45%. Locoregional control rates seem improved with cisplatin-based combinations. Acute and late toxicity was similar across CC protocols. An increase in acute toxicity was found with cisplatin-based combinations and with neoadjuvant and adjuvant chemotherapy. Quality of life (QoL) was reported in five trials, there were no decrease in general, gastro-intestinal or urinary QoL. Little data on elderly patients is available.

Conclusion:

With similar efficacy and toxicity profiles, and in the absence of comparability amongst trials, the question of the optimal CC requires further clinical investigations.

Keywords: Bladder cancer, trimodal treatment, chemotherapy

1036

Digital Poster

18 F-flotufolastat and 18 F-rhPSMA-7 PET-guided salvage radiotherapy for recurrent prostate cancer

Marco M. E. Vogel 1,2 , Jürgen E. Gschwend 3 , Jan C. Peeken 1,2,4 , Isabel Rauscher 5 , Stephanie E. Combs 1,2,4 , Matthias Eiber 5 1 Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany. 2 Institute for Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Zentrum München, Neuherberg, Germany. 3 Department of Urology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany. 4 Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany. 5 Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany

Purpose/Objective:

More than a third of patients with prostate cancer experience a biochemical recurrence (BCR) after undergoing initial treatment with radical prostatectomy (RP). Such patients will undergo salvage radiotherapy (SRT). Prostate-